These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34210493)

  • 1. Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening.
    Byrne L; Toland AE
    Urol Clin North Am; 2021 Aug; 48(3):387-399. PubMed ID: 34210493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Chen F; Madduri RK; Rodriguez AA; Darst BF; Chou A; Sheng X; Wang A; Shen J; Saunders EJ; Rhie SK; Bensen JT; Ingles SA; Kittles RA; Strom SS; Rybicki BA; Nemesure B; Isaacs WB; Stanford JL; Zheng W; Sanderson M; John EM; Park JY; Xu J; Wang Y; Berndt SI; Huff CD; Yeboah ED; Tettey Y; Lachance J; Tang W; Rentsch CT; Cho K; Mcmahon BH; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Sellers TA; Yamoah K; Murphy AB; Crawford DC; Patel AV; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas CM; Stern MC; Kote-Jarai Z; Govindasami K; Cook MB; Chokkalingam AP; Hsing AW; Goodman PJ; Hoffmann TJ; Drake BF; Hu JJ; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Idowu MO; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Diop H; Van Den Eeden SK; Blanchet P; Fowke JH; Casey G; Hennis AJ; Lubwama A; Thompson IM; Leach R; Easton DF; Preuss MH; Loos RJ; Gundell SM; Wan P; Mohler JL; Fontham ET; Smith GJ; Taylor JA; Srivastava S; Eeles RA; Carpten JD; Kibel AS; Multigner L; Parent MÉ; Menegaux F; Cancel-Tassin G; Klein EA; Andrews C; Rebbeck TR; Brureau L; Ambs S; Edwards TL; Watya S; Chanock SJ; Witte JS; Blot WJ; Michael Gaziano J; Justice AC; Conti DV; Haiman CA
    Eur Urol; 2023 Jul; 84(1):13-21. PubMed ID: 36872133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
    Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
    BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polygenic risk score in prostate cancer.
    Oh JJ; Hong SK
    Curr Opin Urol; 2022 Sep; 32(5):466-471. PubMed ID: 35855560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk.
    Machiela MJ; Chen CY; Chen C; Chanock SJ; Hunter DJ; Kraft P
    Genet Epidemiol; 2011 Sep; 35(6):506-514. PubMed ID: 21618606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
    Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
    JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
    Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
    J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers.
    Mars N; Koskela JT; Ripatti P; Kiiskinen TTJ; Havulinna AS; Lindbohm JV; Ahola-Olli A; Kurki M; Karjalainen J; Palta P; ; Neale BM; Daly M; Salomaa V; Palotie A; Widén E; Ripatti S
    Nat Med; 2020 Apr; 26(4):549-557. PubMed ID: 32273609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic evaluation of narrow-sense validity of polygenic risk score for prostate cancer in a Chinese prostate biopsy cohort.
    Wu Y; Ruan X; Gao P; Da H; Fang Z; Xu D; Jiang H; Ding Q; Lin X; Lu D; Na R
    Clin Genet; 2023 Jun; 103(6):636-643. PubMed ID: 36840471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
    Amin Al Olama A; Benlloch S; Antoniou AC; Giles GG; Severi G; Neal DE; Hamdy FC; Donovan JL; Muir K; Schleutker J; Henderson BE; Haiman CA; Schumacher FR; Pashayan N; Pharoah PD; Ostrander EA; Stanford JL; Batra J; Clements JA; Chambers SK; Weischer M; Nordestgaard BG; Ingles SA; Sorensen KD; Orntoft TF; Park JY; Cybulski C; Maier C; Doerk T; Dickinson JL; Cannon-Albright L; Brenner H; Rebbeck TR; Zeigler-Johnson C; Habuchi T; Thibodeau SN; Cooney KA; Chappuis PO; Hutter P; Kaneva RP; Foulkes WD; Zeegers MP; Lu YJ; Zhang HW; Stephenson R; Cox A; Southey MC; Spurdle AB; FitzGerald L; Leongamornlert D; Saunders E; Tymrakiewicz M; Guy M; Dadaev T; Little SJ; Govindasami K; Sawyer E; Wilkinson R; Herkommer K; Hopper JL; Lophatonanon A; Rinckleb AE; Kote-Jarai Z; Eeles RA; Easton DF; ; ;
    Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1121-9. PubMed ID: 25837820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygenic risk scores for prostate cancer: testing considerations.
    Toland AE
    Can J Urol; 2019 Oct; 26(5 Suppl 2):17-18. PubMed ID: 31629419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review.
    Song SH; Byun SS
    Investig Clin Urol; 2021 May; 62(3):256-266. PubMed ID: 33943048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
    Huntley C; Torr B; Sud A; Rowlands CF; Way R; Snape K; Hanson H; Swanton C; Broggio J; Lucassen A; McCartney M; Houlston RS; Hingorani AD; Jones ME; Turnbull C
    Lancet Oncol; 2023 Jun; 24(6):658-668. PubMed ID: 37178708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
    Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
    Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of prostate cancer and its utility in treatment and screening.
    Benafif S; Ni Raghallaigh H; McHugh J; Eeles R
    Adv Genet; 2021; 108():147-199. PubMed ID: 34844712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
    Ruan X; Huang D; Huang J; Tsu JH; Na R
    J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis.
    Siltari A; Lönnerbro R; Pang K; Shiranov K; Asiimwe A; Evans-Axelsson S; Franks B; Kiran A; Murtola TJ; Schalken J; Steinbeisser C; Bjartell A; Auvinen A;
    Clin Genitourin Cancer; 2023 Apr; 21(2):316.e1-316.e11. PubMed ID: 36243664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer.
    Plym A; Penney KL; Kalia S; Kraft P; Conti DV; Haiman C; Mucci LA; Kibel AS
    J Natl Cancer Inst; 2022 May; 114(5):771-774. PubMed ID: 33792693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.